Nothing Special   »   [go: up one dir, main page]

MX2017003841A - Anticuerpos anti-il-25 y usos de los mismos. - Google Patents

Anticuerpos anti-il-25 y usos de los mismos.

Info

Publication number
MX2017003841A
MX2017003841A MX2017003841A MX2017003841A MX2017003841A MX 2017003841 A MX2017003841 A MX 2017003841A MX 2017003841 A MX2017003841 A MX 2017003841A MX 2017003841 A MX2017003841 A MX 2017003841A MX 2017003841 A MX2017003841 A MX 2017003841A
Authority
MX
Mexico
Prior art keywords
antibodies
human
bind
disease
certain embodiments
Prior art date
Application number
MX2017003841A
Other languages
English (en)
Inventor
M Orengo Jamie
ALLINNE Jeanne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017003841A publication Critical patent/MX2017003841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a interleuquina-25 (IL-25) humana y métodos de uso de los mismos. De acuerdo a ciertas realizaciones, los anticuerpos de la invención se unen a lL-25 humana con alta afinidad. En ciertas realizaciones, la invención incluye los anticuerpos que se unen a lL-25 humana y bloquea señalización celular mediada por IL-25. Los anticuerpos de la invención pueden ser anticuerpos humanos de ocurrencia no natural. Los anticuerpos de la invención son útiles para el tratamiento de varios trastornos asociados con actividad o expresión de lL-25, incluyendo asma, alergia, enfermedad pulmonar obstructiva crónica (EPOC), enfermedad inflamatoria intestinal (EII), incluyendo colitis ulcerosa y enfermedad de Crohn, dermatitis atópica (DA), y Granulomatosis eosinofílica con poliangitis (EGPA), también conocido como síndrome de Churg-Strauss.
MX2017003841A 2014-09-23 2015-09-22 Anticuerpos anti-il-25 y usos de los mismos. MX2017003841A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462054167P 2014-09-23 2014-09-23
PCT/US2015/051407 WO2016049000A2 (en) 2014-09-23 2015-09-22 Anti-il-25 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017003841A true MX2017003841A (es) 2018-02-23

Family

ID=54207847

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003841A MX2017003841A (es) 2014-09-23 2015-09-22 Anticuerpos anti-il-25 y usos de los mismos.

Country Status (18)

Country Link
US (3) US9840557B2 (es)
EP (1) EP3197914B1 (es)
JP (2) JP6694877B2 (es)
KR (1) KR102576368B1 (es)
CN (1) CN107207589B (es)
AU (1) AU2015321517B2 (es)
CA (1) CA2961517C (es)
CL (2) CL2017000703A1 (es)
CO (1) CO2017003072A2 (es)
EA (1) EA036658B1 (es)
IL (1) IL251001B (es)
MA (1) MA40106A1 (es)
MX (1) MX2017003841A (es)
MY (1) MY185832A (es)
PH (1) PH12017500403A1 (es)
SG (2) SG11201701712WA (es)
WO (1) WO2016049000A2 (es)
ZA (1) ZA201701663B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003841A (es) 2014-09-23 2018-02-23 Regeneron Pharma Anticuerpos anti-il-25 y usos de los mismos.
EA202190162A3 (ru) 2016-04-27 2021-11-30 Эббви Инк. Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
KR20230164197A (ko) * 2017-04-13 2023-12-01 리제너론 파마슈티칼스 인코포레이티드 Il33 및 il1rl1을 코딩하는 유전자에서의 위험 대립유전자를 갖는 환자에서의 폐 질환의 치료 및 저해
CN107213463A (zh) * 2017-05-24 2017-09-29 清华大学 白介素25在银屑病的发育中的作用
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
CN112638940B (zh) * 2018-11-19 2022-09-30 苏州鑫康合生物医药科技有限公司 抗-il-25抗体及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2022150660A1 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
WO2023160610A1 (en) * 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof
WO2024206768A1 (en) * 2023-03-31 2024-10-03 Novarock Biotherapeutics, Ltd. Anti-il-25 antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2041177B1 (en) 2006-06-02 2011-12-14 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
GB0707505D0 (en) * 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
GB0817891D0 (en) 2008-09-30 2008-11-05 Medical Res Council Antibodies against il-25
SG184195A1 (en) 2010-03-30 2012-11-29 Janssen Biotech Inc Humanized il-25 antibodies
WO2012097126A2 (en) * 2011-01-13 2012-07-19 The University Of Maryland, Baltimore Il-25 treatment of obesity and metabolic disorders
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
MX2017003841A (es) 2014-09-23 2018-02-23 Regeneron Pharma Anticuerpos anti-il-25 y usos de los mismos.

Also Published As

Publication number Publication date
CA2961517A1 (en) 2016-03-31
AU2015321517B2 (en) 2021-02-18
SG11201701712WA (en) 2017-04-27
IL251001B (en) 2021-04-29
EA201790441A1 (ru) 2017-08-31
SG10201913084PA (en) 2020-03-30
US20180057583A1 (en) 2018-03-01
CA2961517C (en) 2023-05-02
MA40106A1 (fr) 2018-06-29
AU2015321517A1 (en) 2017-04-06
CL2018003608A1 (es) 2019-03-15
WO2016049000A3 (en) 2016-05-06
JP2017533888A (ja) 2017-11-16
CL2017000703A1 (es) 2017-12-29
JP6916319B2 (ja) 2021-08-11
CN107207589A (zh) 2017-09-26
JP6694877B2 (ja) 2020-05-20
EP3197914A2 (en) 2017-08-02
EA036658B1 (ru) 2020-12-04
US20160083466A1 (en) 2016-03-24
CN107207589B (zh) 2021-04-06
KR20170063671A (ko) 2017-06-08
EP3197914B1 (en) 2024-02-07
US11542326B2 (en) 2023-01-03
IL251001A0 (en) 2017-04-30
US10640558B2 (en) 2020-05-05
PH12017500403A1 (en) 2017-07-17
JP2020075926A (ja) 2020-05-21
NZ730105A (en) 2024-01-26
MY185832A (en) 2021-06-11
CO2017003072A2 (es) 2017-06-30
ZA201701663B (en) 2023-04-26
WO2016049000A2 (en) 2016-03-31
BR112017005692A2 (pt) 2017-12-12
KR102576368B1 (ko) 2023-09-08
US20200262912A1 (en) 2020-08-20
US9840557B2 (en) 2017-12-12

Similar Documents

Publication Publication Date Title
PH12017500403A1 (en) Anti-il-25 antibodies and uses thereof
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
MX2023004306A (es) Un antagonista de il-4r para usarse en prevenir o tratar la alergia.
PH12018502113A1 (en) Chimeric receptors and methods of use thereof
MX2018007423A (es) Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
MX371498B (es) Anticuerpos anti-activina a y usos de los mismos.
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MY193249A (en) Anti-human cd19 antibodies with high affinity
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
NZ722042A (en) Antibody molecules to tim-3 and uses thereof
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
MX2017010336A (es) Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
NZ710726A (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
WO2014151456A3 (en) Treatment of inflammatory diseases
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX2020006494A (es) Anticuerpos de cadena pesada que se unen a cd22.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
MX2017007953A (es) Tratamiento de la degeneración de la retina mediante el uso de células progenitoras.
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
MX362854B (es) Siarn y su uso en los metodos y composiciones para el tratamiento y/o prevencion de enfermedades de los ojos.